In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boca Pharmacal LLC

Latest From Boca Pharmacal LLC

Endo Makes A Play For Auxilium, But QLT Deal Gets In The Way

The Irish company made its interest for Auxilium public, but the takeover target is not ready to break its previous merger agreement with Canadian drugmaker QLT.

BioPharmaceutical Strategy

Earnings Briefs: Valeant, Vertex, BioMarin, Endo, Hospira

Valeant attributes 14% organic growth in U.S. sales to Bausch + Lomb acquisition, disputing Allergan assertion that the deal has not borne fruit. Vertex sees evidence of sustained benefit for CF patients in Kalydeco long-term usage study. Other updates from the second quarter earnings calls, in brief.

BioPharmaceutical Business Strategies

Deal Watch: Auxilium Joins The Tax-Inversion Wave As BIO Keeps The Deal Tide High

Endo expanded its generics business by purchasing Dava, EMD Serono partnered with Mersana on antibody-drug conjugates and Ligand in-licensed a cancer and autoimmune disease candidate from TG Therapeutics. It was all part of a hectic deal-making week coinciding with the annual BIO conference in San Diego.

BioPharmaceutical Deals

Endo Buys Dava, Building In Generics

The acquisitive specialty pharma will buy privately-held generics firm Dava Pharmaceuticals for $575 million in cash and potentially another $25 million based on the achievement of certain sales milestones.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer